- Home
- STEC vs CARM Comparison
STEC vs CARM Comparison
Compare STEC & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- CARM
- Stock Information
- Founded
- STEC 2006
- CARM 2016
- Country
- STEC China
- CARM United States
- Employees
- STEC N/A
- CARM N/A
- Industry
- STEC
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- CARM Health Care
- Exchange
- STEC NYSE
- CARM Nasdaq
- Market Cap
- STEC 19.0M
- CARM 19.7M
- IPO Year
- STEC 2021
- CARM N/A
- Fundamental
- Price
- STEC $0.65
- CARM $0.45
- Analyst Decision
- STEC
- CARM Hold
- Analyst Count
- STEC 0
- CARM 5
- Target Price
- STEC N/A
- CARM $4.57
- AVG Volume (30 Days)
- STEC 104.8K
- CARM 514.4K
- Earning Date
- STEC 03-04-2025
- CARM 03-31-2025
- Dividend Yield
- STEC N/A
- CARM N/A
- EPS Growth
- STEC N/A
- CARM N/A
- EPS
- STEC N/A
- CARM N/A
- Revenue
- STEC $260,474,693.00
- CARM $20,268,000.00
- Revenue This Year
- STEC $9.76
- CARM $46.34
- Revenue Next Year
- STEC $15.85
- CARM N/A
- P/E Ratio
- STEC N/A
- CARM N/A
- Revenue Growth
- STEC N/A
- CARM 41.13
- 52 Week Low
- STEC $0.20
- CARM $0.38
- 52 Week High
- STEC $3.25
- CARM $2.77
- Technical
- Relative Strength Index (RSI)
- STEC 46.73
- CARM 44.17
- Support Level
- STEC $0.50
- CARM $0.43
- Resistance Level
- STEC $0.81
- CARM $0.50
- Average True Range (ATR)
- STEC 0.08
- CARM 0.05
- MACD
- STEC -0.00
- CARM 0.00
- Stochastic Oscillator
- STEC 48.13
- CARM 28.16
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.